CONVINCE试验健康经济学评价:高剂量在线血液透析滤过对比高通量血液透析的成本-效用
基于多国随机对照CONVINCE试验,从社会视角评估高剂量在线血液透析滤过(HDF)对比高通量血液透析(HD)的成本-效用。两年试验内HDF的增量成本效果比(ICER)为€31,898或€37,344(取决于透析人员成本),终身Markov模型ICER为€27,068或€36,751。在€50,000/QALY支付阈值下,HDF具有成本效果的概率超过90%。
要点
- 支付阈值€50,000/QALY时,HDF具有成本效果的概率>90%。
- 成本效果主要驱动因素为延长的生命年中额外透析次数,而非单次透析成本。
核心结论
- 与高通量HD相比,高剂量HDF以更高成本获得更多QALYs,在€50,000/QALY阈值下很可能具有成本效果。
研究设计与样本
- 基于多国随机对照CONVINCE试验的社会视角成本-效用分析,使用Markov队列模型外推至终身时限。
- 成本基于已发表数据,设置两种透析人员成本情景;其他资源使用、生产力损失和生活质量通过电子病例报告表或国家适配自报问卷收集。
主要发现
- 两年试验分析中,HDF的ICER为€31,898和€37,344(取决于透析人员成本)。
- 终身Markov模型分析中,ICER为€27,068和€36,751。
- 终身分析敏感性分析显示,€50,000/QALY阈值下具有成本效果的概率>90%。
- 排除额外生命年中的所有成本后,ICER为€13,231。
关键数值与推荐
- 增量成本效果比(ICER):两年试验分析€31,898和€37,344;终身模型€27,068和€36,751。
- 支付意愿阈值€50,000/QALY时,成本效果概率>90%。
- 排除额外生命年所有成本后ICER为€13,231。
临床怎么用
- 结果提示HDF在较高支付阈值下可能具有成本效果,但成本因国家和中心而异,建议将结果转化至本地环境。
- 成本效果主要驱动于延长生命年中的额外透析次数,而非单次透析成本。
局限性
- 成本基于已发表数据及两种透析人员成本情景,可能因国家和中心不同而存在差异。
- 终身结果依赖Markov模型外推,试验仅提供两年数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
High-flux hemodialysis (HD) and high-dose hemodiafiltration (HDF) are established treatments for patients with kidney failure. Since HDF has been associated with improved survival rates compared to HD, we evaluated the cost-effectiveness of HDF compared to HD. Cost-utility analyses were performed from a societal perspective alongside the multinational randomized controlled CONVINCE trial. A Markov cohort model was used to extrapolate results to a lifetime time horizon. Costs of dialysis sessions were based on published data, with two scenarios reflecting different estimates for costs of dialysis staff. Other healthcare resource use, productivity losses and quality of life were collected in the electronic case report form or by country-adapted, self-reported questionnaires. Scenario and probabilistic sensitivity analyses were performed. In the two-year trial-based analysis, HDF was associated with higher quality-adjusted life years (QALYs) and higher costs, with incremental costs per QALY (ICER) of €31,898 and €37,344, depending on dialysis staff costs. The lifetime Markov cohort model resulted in ICERs of €27,068 and €36,751. Compared to HD, HDF resulted in an additional year in perfect health at increased costs. Sensitivity analyses of the lifetime analyses showed the probability of cost-effectiveness was more than 90% at willingness-to-pay threshold of €50,000/QALY. The ICER was €13,231 when excluding all costs in additional life years. The probability of cost-effectiveness was mainly driven by costs due to additional dialysis sessions in life years gained, and not due to additional costs per dialysis session. As costs may differ between countries and centers, we recommend translating our results to local settings.
引用
- Schouten AEM, Fischer F, Blankestijn PJ, et al. A health economic evaluation of the multinational, randomized controlled CONVINCE trial: cost-utility of high-dose online hemodiafiltration compared to high-flux hemodialysis. Kidney Int. 2025. PMID: 39848405. doi:10.1016/j.kint.2024.12.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。